Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 10. (Cancelled).

11. (Original) An inhalable solid pharmaceutical formulation comprising

(a) an active ingredient substance susceptible to chemical interaction with lactose which active ingredient is selected from:
3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl] oxy}butyl) benzenesulfonamide;
3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide;
4-{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,
or a salt, solvate or physiologically acceptable derivative thereof;

(b) lactose and

(c) magnesium stearate.

12. (Currently Amended) An inhalable solid pharmaceutical formulation as claimed in claim 11 ~~further comprising one or more of the features described in any one or more of claims 3 to 10~~ wherein the magnesium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

13. (Currently Amended) An inhalable solid pharmaceutical formulation as claimed in claim 11 ~~or claim 12~~ wherein the active ingredient substance is 3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl] oxy}butyl) benzenesulfonamide; or a salt, solvate or physiologically acceptable derivative thereof, and the carrier is lactose.

14. (Original) A method of reducing or inhibiting chemical interaction between an active ingredient substance and a carrier susceptible to chemical interaction, which comprises mixing magnesium stearate with said active ingredient substance and said carrier.

15. (Original) A method of inhibiting chemical degradation of an active ingredient substance in a formulation comprising a carrier and an active ingredient substance, which method comprises mixing magnesium stearate with said active ingredient substance and said carrier.

16. (Currently Amended) A method as claimed in claim 14 ~~or 15 further comprising one or more of the features described in any one or more of claims 3 to 10~~ wherein the carrier is a reducing sugar.

17. (Cancelled).

18. (Currently Amended) A method for treating asthma, chronic obstructive pulmonary disease (COPD), chronic or wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, or rhinitis, comprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation as claimed in claim 11 ~~to 13~~.

19. (Original) A method of preparing a solid pharmaceutical preparation comprising combining in one or more steps: (a) an active ingredient substance susceptible to interaction with a carrier, (b) a carrier and (c) magnesium stearate.

20. (New) An inhalable solid pharmaceutical formulation as claimed in claim 11, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

21. (New) A method as claimed in claim 16, wherein the carrier is lactose.

22. (New) A method as claimed in claim 14, wherein the magnesium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

23. (New) A method as claimed in claim 14, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

24. (New) A method as claimed in claim 14, wherein said drug substance is selected from:
3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl] oxy}butyl) benzenesulfonamide;
3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide;
4-{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,
or a salt, solvate or physiologically acceptable derivative thereof.

25. (New) A method as claimed in claim 14, wherein the active ingredient substance is 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl); or a salt, solvate or physiologically acceptable derivative thereof, and the carrier is lactose.